Skip to main content

Table 4 Relationship between trough blood concentration and side effects observed in patients taking bosutinib

From: Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia

  Distribution of C0 P
Q1 Q2–3 Q4
Liver dysfunction
 ≥ grade 1 6/34 29/68 15/34 0.019
 ≥ grade 2 0/34 2/68 4/34 0.050
 ≥ grade 3–4 0/34 1/68 2/34 0.231
Diarrhea
 ≥ grade 1 5/34 8/68 6/34 0.714
 ≥ grade 2 1/34 2/68 5/34 0.041
 ≥ grade 3 1/34 0/68 4/34 0.012
  1. Q quantile, C 0 trough blood concentration. Q1 (≤ 32.5), Q2 (> 32.5), Q3 (≤ 91.0), Q4 (> 91.0). Median C0 = 54.0 (ng/mL)